Japanese
Titleバセドウ病の甲状腺重量別131I治療成績
Subtitle原著
Authors五味由加利*, 浜田昇***, 吉村弘**, 石川直文**, 百渓尚子**, 伊藤國彦**, 井上健*, 鈴木晟時*
Authors(kana)
Organization*昭和大学藤が丘病院内科内分泌代謝科, **伊藤病院, ***大阪福祉事業財団すみれ病院
Journal核医学
Volume34
Number12
Page1131-1138
Year/Month1997/12
Article原著
Publisher日本核医学会
Abstract「要旨」バセドウ病の甲状腺重量別131I治療において, 従来のプロトコール(旧プロトコール)から, 甲状腺重量が50g以上の症例で, 期待吸収線量を5〜20Gy/g tissue 増量した新しいプロトコール(新プロトコール)に変更して治療を行い, その5年後の成績を検討した. 治療成績の評価は, 治療後の甲状腺機能を低下, 潜在性低下, 正常, 潜在性亢進, 亢進に分類して行った. その際, できるだけ1回の治療で甲状腺機能の正常化を目指すというこの治療法の目的から, 2回以上治療を行った症例は, すべて亢進とみなした. その結果, 新旧両プロトコールの低下, 正常の頻度はともに差はなく, 新プロトコールの方が有意に亢進が減少していた(p<0.05). バセドウ病の甲状腺重量別131I治療法を改定することで, 低下の頻度を増やすことなく亢進を減らすことができ, 治療成績の改善を得た.
Practice臨床医学：一般
KeywordsGraves' disease, 131I treatment, Adjusted accumulation dose, Thyroid weight
English
TitleThe Outcome of Adjusted Accumulation Dose of Treatment of Graves' Disease
SubtitleOriginal Articles
AuthorsYukari GOMI*, Noboru HAMADA***, Hiroshi YOSHIMURA**, Naofumi ISHIKAWA**, Naoko MOMOTANI**, Kunihiko ITO**, Takeshi INOUE*, Seiji SUZUKI*
Authors(kana)
Organization*Division of Endocrinology and Metabolism, Department of Internal Medicine, Showa University Fujigaoka Hospital, **Ito Hospital, ***Sumire Hospital
JournalThe Japanese Journal of nuclear medicine
Volume34
Number12
Page1131-1138
Year/Month1997/12
ArticleOriginal article
PublisherTHE JAPANESE SOCIETY OF NUCLEAR MEDICINE
AbstractWe evaluated the outcome of 131I treatment of Graves' disease in two different protocols (old and new protocol) of adjusted accumulation dose from 1988 to 1995. Adjusted accumulation doses of patients with above 50 g thyroid weights were increased by 5 - 20 Gy/g tissue in new protocol compared to those in old one. In 166 patients treated with single and plural doses of 131I treatment in 1990 (Group In), the therapeutic doses were calculated according to new protocol and in 130 patients in 1988 (Group Io), according to old one, modification of Quimby's formula. The patients treated with plural doses were classified as hyperthyroidism because the efficacies of the first treatments with 131I were insufficient. At the 5-yr follow up, the incidence of hypothyroid in Group In was 9%, subclinical hypothyroid 17%, euthyroid 30%, subclinical hyperthyroid 7%, hyperthyroid 37%. In Group Io, 11% of the patients were hypothyroid, 6% subclinical hypothyroid, 29% euthyroid, 3% subclinical hyperthyroid, 51% hyperthyroid. The incidence of hyperthyroid in Group In was lower than that in Group Io (p < 0.05). There were no significant differences in hypothyroid and euthyroid. In conclusion, we suggest that an adjusted dose of 131I in relation to the patients' thyroid weight shows some room for improvement.
PracticeClinical medicine
KeywordsGraves' disease, 131I treatment, Adjusted accumulation dose, Thyroid weight

【全文PDF】